Involvement of the Ubiquitin-Proteasome System in the Formation of Experimental Postsurgical Peritoneal Adhesions by Di Filippo, Clara et al.
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2012, Article ID 194723, 7 pages
doi:10.1155/2012/194723
Research Article
Involvement of the Ubiquitin-Proteasome System in the
Formation of Experimental Postsurgical Peritoneal Adhesions
ClaraDiFilippo,1 PasqualePetronella,2 Fulvio Freda,2 Marco Scorzelli,2
Marco Ferretti,2 SivestroCanonico,2 Francesco Rossi,1 andMicheleD’Amico1
1Department of Experimental Medicine, Section of Pharmacology “L. Donatelli”, Second University of Naples, 80138 Naples, Italy
2Department of Gerontology, Geriatric and Metabolic Diseases, Second University of Naples, 80138 Naples, Italy
Correspondence should be addressed to Michele D’Amico, michele.damico@unina2.it
Received 26 July 2011; Revised 31 October 2011; Accepted 5 November 2011
Academic Editor: Wolfgang Neuhofer
Copyright © 2012 Clara Di Filippo et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
We investigated the Ubiquitin-Proteasome System (UPS), major nonlysosomal intracellular protein degradation system, in the
genesis of experimental postsurgical peritoneal adhesions. We assayed the levels of UPS within the adhered tissue along with the
development of peritoneal adhesions and used the speciﬁc UPS inhibitor bortezomib in order to assess the eﬀect of the UPS
blockade on the peritoneal adhesions. We found a number of severe postsurgical peritoneal adhesions at day 5 after surgery
increasing until day 10. In the adhered tissue an increased values of ubiquitin and the 20S proteasome subunit, NFkB, IL-6, TNF-
α and decreased values of IkB-beta were found. In contrast, bortezomib-treated rats showed a decreased number of peritoneal
adhesions, decreased values of ubiquitin and the 20S proteasome, NFkB, IL-6, TNF-α, and increased levels of IkB-beta in the
adhered peritoneal tissue. The UPS system, therefore, is primarily involved in the formation of post-surgical peritoneal adhesions
in rats.
1.Introduction
Postsurgicaladhesionsarepolymorphicclinicalpicturesran-
ging from abdominal and pelvic pain to intestinal mechan-
ical occlusion. They are due to stable lesions scarring, the
adhesions. Intraperitoneal adhesions are connective bridges
between adjacent portions of the peritoneum [1], their for-
mation occurs in approximately 90% of patients undergoing
abdominal surgery, and it is an important reason of post-
operative morbidity and mortality [2].
Adhesions formation is initiated by the trauma surgery,
and it is supported by a number of factors including ﬁbrin,
thromboplastin, mesothelial cells, ﬁbroblasts, collagen ﬁb-
rils, and the development of a local inﬂammatory process,
among others [3].
Until a few years ago to prevent the formation of ad-
hesions, the focus was mainly on the procedures to be
implemented during surgery. It is worth mentioning that
there is considerable consensus that laparoscopic surgery is
associated with the reduced development of adhesions
compared to open surgery in the international arena [4, 5].
A surgical trauma stimulates the release of several chem-
ical mediators of inﬂammation, including IL-1, IL-6, and
TNF-α whose involvement in the inﬂammatory process, that
underlies the formation of adhesions, has been documented
in many studies [6].
The transforming growth factor beta-1 (TGF-β1) and
transforming growth factor beta-3 (TGF-β3) appear to be
involved in the process too. They are released after hypoxia
generated by tissue injury during surgery [7].
I nr e c e n ty e a r sn u m e r o u ss t u d i e sh a v eb e e na i m e da ta
likely pharmacological prevention of postsurgical adhesion
formation. For example, some authors proposed the use of
statins as they are considered as being able to increase the
peritoneal ﬁbrinolysis [8]. Other authors have suggested that
interferon gamma is a possible therapeutic target to prevent
the formation of adhesions, due to its crucial role in the
diﬀerential regulation of PAI-1 and t-PA, which are involved
in this process [9]. However other ones suggest the use of
antitack agents such as carboxymethylcellulose and hyalu-
ronicacidresorbablemembranes.Finallyitisalsoallegedthe
possible use of propofol [10].2 Mediators of Inﬂammation
In this wide scenario of hypotheses we want to include
the centrality of the inﬂammatory component in the unfold-
ing process of adhesions; we hypothesized that the Ubiq-
uitin-Proteasome System (UPS), the major nonlysosomal
intracellular protein degradation system in eukaryotic cells
andwhichiscapableofinducinginﬂammation[11–14],may
play a major role in the formation of post-surgical peritoneal
adhesions. We hypothesized that the activation of this system
during the surgery can be suggestive of the beginning of
inﬂammatoryeventsthatincascadeleadtoadhesionsforma-
tion. So, in this experimental study on rats we have evaluated
whether changes in UPS levels and activity into the adhered
tissue occur along with the development of post-surgical
peritoneal adhesions, and then we used the speciﬁc UPS
inhibitor bortezomib [15–17] in order to ascertain the role
thattheUPSmayhaveintheperitonealadhesionsformation.
2. Methods
2.1. Surgical Procedure. All experimental procedures and
protocols used in this study were reviewed and approved
by the Special Ethics Commission at the 2nd University of
Naples.
The surgery was performed as previously described [4].
Male Sprague-Dawley rats (n = 15) were marked with a
pencil as 1 to 15, anesthetized with urethane (1.2g/kgip),
subjected to midline laparotomy. A sample of parietal peri-
toneal tissue was taken and an enterotomy was performed at
the level of the ileum. The surgical incision was sutured with
absorbable surgical wire 4/0 in order to induce an inﬂam-
matory peritoneal insult. All of the surgical procedure was
then ended by a nonabsorbable suture, and the rats were
placed in the recovering room for awakening. Five days after
the surgery the rats were subjected to another laparotomy,
had a new tissue sample taken, and were assayed for the
development of peritoneal adhesions by means of qualitative
and quantitative evaluation. A score from 1 to 6 was estab-
lished, and it was given as follows: 1 to the presence of poor
and lapse adhesions in a limited peritoneal zone; 2 to the
presence of poor adhesions in an extended zone; 3 to the
presence of several lapse adhesions into the peritoneum; 4 to
the presence of localized dense adhesions; 5 to the presence
of extended dense adhesions with access to peritoneal cavity;
6tothepresenceofextendeddenseadhesionsandimpossible
access to peritoneal cavity. The same procedure was repeated
after 10 days from the ﬁrst surgery, having particular atten-
tion to keep always the same rat numbering over the time
course considered. A surgeon blinded for the procedure and
diﬀerent from the one who performed the surgery scored the
adhesion. Biopsies of peritoneal tissue were snap-frozen and
used to determine: TNF-alpha, IL6, NFkB, and activity of the
UPS system.
2.1.1. Experimental Groups. The study was conducted on
maleSprague-Dawleyrats(4-montholdandweighing200g)
induced with only the surgical procedure (n = 15) or
treated with bortezomib + surgical procedure (n = 15). This
latterwasﬁrsttreatedwithbortezomib(Velcade;Millennium
Pharmaceuticals, Cambridge, UK) by intravenous injection
(0.05mg/kg) given 1 hour before surgery, and a second
injection was given 1 hour after the surgical procedure (total
dose of 0.1mg/kg) according to our previous experience in
other setting [4].
There were no signiﬁcant side eﬀects after injections.
2.1.2. Biochemical Parameters Assessed. T h et i s s u es a m p l e s
taken during the surgery were homogenized in 50mM Tris-
HCl (pH 7.2) containing leptin 1μM, pepsatin A 1μM, and
phenyl methyl sulfonyl ﬂuoride 200μM and centrifuged for
10min at 10,000 ×ga t4 ◦C.
200μL of homogenate were used to determine total pro-
tein according to the Bradford’s method. The levels of ubiq-
uitin, IL-6, and TNF-alpha were quantiﬁed by a commercial
colorimetric ELISA kit (R&D Systems, USA). For the quan-
titative measurement of the 20S proteasome, a speciﬁc SDS
activationkit(BostonBiochem,USA)wasusedfollowingthe
instructions of the manufacturer.
2.1.3. Statistics. Data are presented as mean ± SE. Continu-
ous variables were compared among the groups of rats with
one-way analysis of variance (ANOVA) for normally distrib-
uted data and Kruskal-Wallis test for nonnormally distrib-
uted data. When diﬀerences were found among the groups,
Bonferroni correction was used to make pairwise compar-
isons. A P<0.05 was considered statistically signiﬁcant. All
calculations were performed using the SPSS2 software.
3. Results
Starting from day 5 from surgery there was a development
of peritoneal adhesions within the rats. After 10 days from
the surgery 7 control rats were scored 6 for the severity of the
adhesions,4ratswerescored5,and4controlratswerescored
1 for the presence of poor and lapse adhesions in a limited
peritoneal zone. An increase in the levels of ubiquitin and
the 20S proteasome within the adhered tissue was observed
in parallel with the development of peritoneal adhesions. For
both the markers this increase was signiﬁcant (P<0.01
versusday0)already5daysaftersurgery(Figure 1).Afurther
increase in the levels of ubiquitin and the 20S proteasome
was observed in the adhered peritoneal tissue after 10 days of
surgery (P<0.01 versus day 0) (Figure 1).
The qualitative evaluation by the peritoneal adhesions
score indicates a substantial decrease of adhesions in the
groupofratstreatedwithbortezomib(e.g.,4ratswerescored
6 and 2 rats were scored 5) after 10 days of surgery if com-
pared with the control group same day (Figure 2). This was
accompinied by a signiﬁcant reduction of the levels of both
ubiquitin and proteasome 20S (P<0.01 versus day 0) in
the peritoneal tissue 5 days after surgery. The reduction
was found to be signiﬁcant even 10 days after surgical
procedure (P<0.01 versus day 0) (Figure 3). At this time
point there was a signiﬁcant correlation between the levels of
ubiquitin/proteasome 20S and the adhesion score assigned
to the rats after bortezomib treatment (Figure 4).Mediators of Inﬂammation 3
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Figure 1: Levels of ubiquitin and 20S proteasome in the tissues from rats during peritoneal adhesions development at time 0, 5, and 10 days
from the surgery in the control group. The diﬀerences from day 0 are considered with ∗P<0.01.
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Figure 2:Quantitative evaluation by theperitonealadhesions scoreindicating asubstantialdecrease ofadhesions inthegroupofratstreated
with bortezomib after 10 days of surgery if compared with the control group same day.
In the rat adhered peritoneal tissue the TNF-alpha, IL-6,
p50, and p65 (subunit of NFkB) levels were signiﬁcantly
increased after 5 and 10 days after surgery (Figure 5). In
contrast, in the same tissue the levels of the IkB-beta both
at day 5 and at day 10 (P<0.01 versus day 0) were seen de-
creased (Figure 6).
Treatment with bortezomib resulted in reduced levels of
TNF-alpha and IL-6, p50, and p65 in both time day 5 and
time day 10 (P<0.01 versus control group with adhesions)
(Figure 5), together with a signiﬁcant increase in levels of
IkB-beta (P<0.01 versus control group) (Figure 6).
4. Discussion
In a previous research this group found that post-surgical
peritoneal adhesions occur in rats when they are subject to
laparatomy and enterotomy of the ileum [4]. These adhe-
sionsarestrictlyrelatedtothetimefromthesurgeryandhave
severity depending on the inﬂammatory response occurring
within the peritoneal specimens, which deteriors the perito-
neal matrix. During this phase, leukocytes, cytokines, che-
mokines, and cell adhesion molecules alters the initial tissut-
al equilibrium predisposing them to the formation of adhe-
sions [4].
In the present study it is shown that a key role in the
tissutal alterations that follows a surgical intervention and
developmentofperitonealadhesionsisassumedbytheUbiq-
uitin-Proteasome System (UPS). This study demonstrates
that the activity of this system, measured on biopsies of
the adhered tissue, relates to the severity of the adhesion;
animals that show high levels of UPS activity also have severe
adhesions, whilst animals that show low levels of UPS have
moderate adhesions.4 Mediators of Inﬂammation
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Figure 3: Levels (ng/mg tissue) of ubiquitin and 20S proteasome in the tissues from rats during peritoneal adhesions development. At time
0, 5, and 10 in the group treated with bortezomib by intravenous injection (0.05mg/kg) given 1 hour before surgery, a second injection was
given 1 hour after the surgical procedure (total dose of 0.1mg/kg) and in the control group. The diﬀerences from day 0 are considered with
∗P<0.01, and the diﬀerences from the control group at the same day are considered as ◦P<0.01.
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Figure 4: Correlation between the adhesion score and the local levels of ubiquitin and protesome 20S 10 days after the surgery.
UPS, generally known as the major pathway for nonlyso-
somal intracellular protein degradation in eukaryotic cells,
was discovered in the eighties by the pioneering work of
Goldberg, Hershko, and their collaborators, using reticulo-
cytelysates[18–20].TheUPSusuallydegradeproteinsintwo
steps. First, the substrate is covalently modiﬁed by addition
of a polyubiquitin chain, through an enzymatic cascade that
involves three classes of factors: E1, the ubiquitin-(Ub-)
activating enzyme [21], E2, a member of the family of Ub-
carriers [22], and E3, a member of the very large family
(several hundred members) of the so-called Ub-ligases [23],
which speciﬁcally recognizes and recruits the substrate of the
ubiquitylation reaction. Second, the ubiquitylated protein is
usually addressed to and degraded by the 26S proteasome, a
giant multisubunit and multicatalytic protease [24]. Due to
its multiple roles, the proteasome is essential in eukaryotes
and its dysfunction has deleterious eﬀects for the cell or
the organism as a whole. In humans, UPS deregulation
has been implicated in a number of pathologies such as
cancer, autoimmune diseases, neurodegenerative diseases, or
viral infections. As a consequence, the proteasome is seen
as a potential therapeutic target in many pathologies [25],
including inﬂammation [26] and possibly now peritoneal
adhesions.
In the present study is also shown that post-operative
adhesions are associated with decreased levels of the inhib-
itory protein for the transcriptor factor nuclear factor kappa
B (NF-kB), the IkB within the adhered tissues, indicating
that one other component in the generation of adhesion is
the activated NF-kB pathway, a central transcription factorMediators of Inﬂammation 5
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Figure 5: Levels (ng/mg tissue) of TNF-alpha, p50, p65, and IL-6 within the tissues from rats during peritoneal adhesions development at
time 0, 5, and 10 days from the peritoneal surgery. The rats were treated or not with bortezomib by intravenous injection (0.05mg/kg) given
1 hour before surgery, and a second injection was given 1 hour after the surgical procedure (total dose of 0.1mg/kg). The diﬀerences from
day 0 are considered with ∗P<0.01, and the diﬀerences from the control group at the same day are considered as ◦P<0.01.
that regulates inﬂammatory genes. Activated NF-kB path-
way leads tissue deregulation and favours cell proliferation
in many circumstances [27–29]. Interestingly, the UPS is
required for activation of NF-kB by degradation of its inhib-
itory IkB proteins [30]. NFkB is normally bound to IkB
in the cytosol; this binding prevents its movement into the
nucleus [31]. Various cellular stimuli, such as inﬂamma-
tory stimuli, induce ubiquitination of phosphorylated IkBs
and subsequent degradation by the proteasome [32, 33].
Degradation of IkBs results in unmasking of the nuclear
localization signal of NF-kB dimers, which subsequently
translocatestothenucleus,whereitinducesthetranscription
of proinﬂammatory cytokines like IL-6 and TNF-α that
play a central role in tissue injury [34]. Here we would
suggest that a surgical insult may induce degradation of IkBs
via ubiquitin-proteasome overactivity, thus enhancing NFkB
activation. This in turn enhances the inﬂammatory potential
of the injured tissue, worsening the peritoneal recovery. A
contention is based on the fact that the levels of UPS, IkB,
TNF-alpha, and IL-6 measured on adhesions biopsies seem
to be related to the severity of the adhesion. Animals that
show moderate levels of UPS, TNF-alpha, and IL-6 have also6 Mediators of Inﬂammation
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Figure 6: IKB-β levels (ng/mg tissue) within the tissues from rats
during peritoneal adhesions development. Rats at time 0, 5, and
10 days from the surgery and treated or not with bortezomib. The
diﬀerences from day 0 are considered with ∗P<0.01, and the
diﬀerences from the control group at the same day are considered
as ◦P<0.01.
less severe adhesions than those with higher levels of these
same mediators.
Proof of concept for a central role of UPS in peritoneal
adhesions is given by the protection from the adhesion for-
mation achieved with the treatment of injured rats with
bortezomib. This drug, initially proposed as anticancer drug
[35],isaspeciﬁcinhibitoroftheUPSactivityandexertsinhi-
bition of the inﬂammation associated to the transcription
factor NFκB, through stabilization of its inhibitor IκB[ 36],
sinceNFκBisboundtoitsinhibitorIκBinthecytoplasmand
is activated by proteasomal degradation of IκB. Inhibition
of proteasome activity prevents degradation of IκBa n d
subsequent activation and translocation of NFκB to the
nucleus to activate downstream pathways [36]. Bortezomib
here is able to reduce the number of rats showing adhesions
and the score assigned to the adhesions, and as consequence
of UPS inhibition, bortezomib also reduced the burden of
inﬂammation occurring in the adhered tissue. At the same
time point, in fact, rats treated with bortezomib had the
lowest level of ubiquitin and proteasome 20S activity, NF-kB
activation, inﬂammatory cells, and cytokine levels associated
with the reduced adhesions formation.
In conclusion, post-surgical peritoneal adhesions forma-
tion is associated with local increased UPS system activity
which is primarily involved in the formation of post-surgical
peritoneal adhesions in rats and with a local inﬂammatory
factors boost.
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